Work

Editorial: Advancing NSCLC treatment: overcoming challenges in immune checkpoint inhibitor therapy

Year: 2026

Type: editorial

Abstract: Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related death, and immune 21 checkpoint inhibitors (ICIs) have revolutionized its treatment by reactivating the immune system to tumor cells [1,2] . Despite significant improvements in patient outcomes, ICIs present 23 several key challenges: inconsistent efficacy across populations, complex resistance mechanisms, 24 and treatment-related toxicities [2,3]

Source: Frontiers in Pharmacology

DOI: 10.3389/fphar.2026.1744580

Authors: Renwang Liu, Yiming Meng, Mohamed Rahouma

Institutions: Tianjin Medical University General Hospital, Tianjin Medical University, Liaoning Cancer Hospital & Institute, Cairo University, Weill Cornell Medicine

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,801